{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T15:12:49Z","timestamp":1726413169021},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T00:00:00Z","timestamp":1148428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,11,2]]},"DOI":"10.1007\/s00280-006-0253-2","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T10:47:41Z","timestamp":1148467661000},"page":"17-21","source":"Crossref","is-referenced-by-count":18,"title":["Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer"],"prefix":"10.1007","volume":"59","author":[{"given":"Keon Woo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"253_CR1","doi-asserted-by":"crossref","unstructured":"Bae JM, Won YJ, Jung KW, Park JG (2002) Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res 34:77","DOI":"10.4143\/crt.2002.34.2.77"},{"key":"253_CR2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587","journal-title":"Br J Cancer"},{"key":"253_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gasric cancer. Cancer 72:37","journal-title":"Cancer"},{"key":"253_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00001813-199602000-00001","volume":"7","author":"DL Schipper","year":"1996","unstructured":"Schipper DL, Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7:137","journal-title":"Anticancer Drugs"},{"key":"253_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163","journal-title":"Ann Oncol"},{"key":"253_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0305-7372(88)90025-4","volume":"15","author":"P Preusser","year":"1998","unstructured":"Preusser P, Achterrath W, Wilke H et al (1998) Chemotherapy of gastric cancer. Cancer Treat Rev 15:257","journal-title":"Cancer Treat Rev"},{"key":"253_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.9-suppl_2-9","volume":"9","author":"EV Cutsem","year":"2004","unstructured":"Cutsem EV (2004) The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologists 9:9","journal-title":"Oncologists"},{"key":"253_CR8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bjc.1994.310","volume":"70","author":"A Sulkes","year":"1994","unstructured":"Sulkes A, Smyth J, Sessa C et al (1994) Docetaxel (Taxotere\u00ae) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380","journal-title":"Br J Cancer"},{"key":"253_CR9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jjco\/hyf057","volume":"32","author":"YJ Bang","year":"2002","unstructured":"Bang YJ, Kang WK, Kang YK et al (2002) 75\u00a0mg\/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32:248","journal-title":"Jpn J Clin Oncol"},{"key":"253_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008342013224","volume":"11","author":"AD Roth","year":"2000","unstructured":"Roth AD, Mailbach R, MArtinelli G et al (2000) Docetaxel (Taxotere)l\u2013cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301","journal-title":"Ann Oncol"},{"key":"253_CR11","first-page":"318s","volume":"22","author":"AD Roth","year":"2004","unstructured":"Roth AD, Mailbach R, Falk S et al (2004) Docetaxel\u2013cisplatin-5-FU (TCF) versus docetaxel\u2013cisplatin (TC) versus epirubicin\u2013visplatin-5-FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 22:318s","journal-title":"J Clin Oncol"},{"key":"253_CR12","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","volume":"23","author":"J Ajani","year":"2005","unstructured":"Ajani J, Fodor M, Tjulandin S et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660","journal-title":"J Clin Oncol"},{"key":"253_CR13","doi-asserted-by":"crossref","first-page":"308s","DOI":"10.1200\/jco.2005.23.16_suppl.4002","volume":"23","author":"V Moiseyenko","year":"2005","unstructured":"Moiseyenko V, Ajani J, Tjulandin S et al (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 23:308s","journal-title":"J Clin Oncol"},{"key":"253_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207","journal-title":"Cancer"},{"key":"253_CR15","first-page":"163","volume":"20","author":"E Kettner","year":"2001","unstructured":"Kettner E, Ridwelski K, Keilholtz U et al (2001) Docetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies. Proc Am Soc Clin Oncol 20:163","journal-title":"Proc Am Soc Clin Oncol"},{"key":"253_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1008328501128","volume":"12","author":"K Ridwelski","year":"2001","unstructured":"Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47","journal-title":"Ann Oncol"},{"key":"253_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1008278103446","volume":"9","author":"V Georgoulias","year":"1998","unstructured":"Georgoulias V, Androulakis N, Dimopoulos AM et al (1998) First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 9:331","journal-title":"Ann Oncol"},{"key":"253_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.bjc.6601891","volume":"91","author":"SH Lee","year":"2004","unstructured":"Lee SH, Kang WK, Park J et al (2004) Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 91:18","journal-title":"Br J Cancer"},{"key":"253_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.coc.0000136018.81814.79","volume":"27","author":"SH Park","year":"2004","unstructured":"Park SH, Kang WK, Lee HR et al (2004) Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 27:477","journal-title":"Am J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0253-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0253-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:21Z","timestamp":1559037981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0253-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,11,2]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0253-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}